RxDoctor Payments Data

John Griffin, MD

Interventional Cardiology · Virginia Beach, VANPI 1740254440

Payments from drug & device makers

$2,089in general payments, 2019–2025

Across 98 payments — averaging $21.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$359
  • Biotronik Inc.$264
  • Johnson & Johnson$219
  • Baxter Healthcare$212
  • Amgen$150
  • Shockwave Medical, Inc$138
  • plus $747 from 20 others

What the payments were for

  • Food & beverage$2,089100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,089 in reported general payments places this provider in the 25th percentile of 176 interventional cardiology providers in Virginia.

See all interventional cardiology providers in Virginia

Medicare billing

Part B allowed, 2024
$244,544
Medicare patients
1,137
Services billed
4,228

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban104$138,113
Repatha SureclickEvolocumab64$71,147
XareltoRivaroxaban52$70,276
EntrestoSacubitril/Valsartan25$47,965
MultaqDronedarone Hcl14$20,598
Dofetilide25$15,067
BrilintaTicagrelor14$14,000
Metoprolol Succinate181$2,149
Rosuvastatin Calcium195$1,787
Ranolazine ErRanolazine14$1,648
Flecainide Acetate44$1,437
Atorvastatin Calcium156$1,435
Diltiazem 24hr Er (Cd)Diltiazem Hcl32$1,245
Ezetimibe63$1,232
Bumetanide19$1,167

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$66$138,113104 claims
Johnson & JohnsonXarelto$219$70,27652 claims
NovartisEntresto$359$47,96525 claims
Sanofi-aventis U.S. LLCMultaq$46$20,59814 claims
AstraZenecaBrilinta$56$14,00014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 176 interventional cardiology providers in Virginia.

Other interventional cardiology in Virginia Beach

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →